Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Powell

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
Nature Communications|October 23, 2023
Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axisJonathan W Lo, Domenico Cozzetto, James L Alexander, et al.
Gut|December 4, 2019
Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cellsNick Powell, Eirini Pantazi, Polychronis Pavlidis, et al.
Gastroenterology|April 29, 2015
Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal InflammationNick Powell, Jonathan W Lo, Paolo Biancheri, et al.
Journal for Immunotherapy of Cancer|July 8, 2021
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximabJames L Alexander, Hajir Ibraheim, Bhavisha Sheth, et al.
Therapeutic Advances in Gastroenterology|August 18, 2025
Non-invasive fluorescence sensing reveals changes in intestinal barrier function and gastric emptying rate in a first-in-human study of Crohn's diseaseJonathan Gan, Qian Chen, Elena Monfort Sanchez, et al.
Gut|February 26, 2015
Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's diseaseJames B Canavan, Cristiano Scottà, Anna Vossenkämper, et al.
Journal of Crohn'S & Colitis|May 1, 2026
What are the top 10 global research priorities for perianal Crohn's disease? The Global Perianal Crohn's Disease Priority Setting PartnershipTheo Pelly, Easan Anand, Jonathan Gower, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort studyZhigang Liu, Kaixing Le, Xin Zhou, et al.
Frontiers in Immunology|January 23, 2023
Type 2 and type 17 effector cells are increased in the duodenal mucosa but not peripheral blood of patients with functional dyspepsiaGrace L Burns, Jessica K Bruce, Kyra Minahan, et al.
Nature Communications|October 3, 2022
Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapyPolychronis Pavlidis, Anastasia Tsakmaki, Eirini Pantazi, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Nature Communications|October 23, 2023
Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axisJonathan W Lo, Domenico Cozzetto, James L Alexander, et al.
Gut|December 4, 2019
Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cellsNick Powell, Eirini Pantazi, Polychronis Pavlidis, et al.
Gastroenterology|April 29, 2015
Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal InflammationNick Powell, Jonathan W Lo, Paolo Biancheri, et al.
Journal for Immunotherapy of Cancer|July 8, 2021
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximabJames L Alexander, Hajir Ibraheim, Bhavisha Sheth, et al.
Therapeutic Advances in Gastroenterology|August 18, 2025
Non-invasive fluorescence sensing reveals changes in intestinal barrier function and gastric emptying rate in a first-in-human study of Crohn's diseaseJonathan Gan, Qian Chen, Elena Monfort Sanchez, et al.
Gut|February 26, 2015
Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's diseaseJames B Canavan, Cristiano Scottà, Anna Vossenkämper, et al.
Journal of Crohn'S & Colitis|May 1, 2026
What are the top 10 global research priorities for perianal Crohn's disease? The Global Perianal Crohn's Disease Priority Setting PartnershipTheo Pelly, Easan Anand, Jonathan Gower, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort studyZhigang Liu, Kaixing Le, Xin Zhou, et al.
Frontiers in Immunology|January 23, 2023
Type 2 and type 17 effector cells are increased in the duodenal mucosa but not peripheral blood of patients with functional dyspepsiaGrace L Burns, Jessica K Bruce, Kyra Minahan, et al.
Nature Communications|October 3, 2022
Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapyPolychronis Pavlidis, Anastasia Tsakmaki, Eirini Pantazi, et al.
Pageof 11